Company facts
- Headquarters
- South San Francisco, California
- Most recent report
- 10-Q, filed Nov 9, 2026
- Incorporated
- Delaware
- Filings on record
- 224 filings
- On EDGAR
- CIK 1842295
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8
News 8 of 17
Prospectuses and Registrations 8 of 11
- POS AM Post-effective amendment to a registration May 12, 2026
- 424B5 Prospectus supplement for an offering Apr 22, 2026
- S-8 Registration statement for an employee plan Feb 4, 2026
- S-3ASR Automatic shelf registration Feb 4, 2026
- 424B3 Prospectus supplement for an offering Nov 6, 2025
- S-1 Registration statement for an offering Oct 17, 2025
- S-8 Registration statement for an employee plan Jan 31, 2025
- 424B4 Final prospectus for an offering Jan 31, 2025
Proxies 2
Ownership 8 of 158
- 4 Insider reported a trade Nov 4, 2026
- 144 Notice of a proposed sale of restricted stock Nov 2, 2026
- 4 Insider reported a trade Oct 30, 2026
- 144 Notice of a proposed sale of restricted stock Oct 29, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Oct 2, 2026
- 144 Notice of a proposed sale of restricted stock Oct 1, 2026
- 4 Insider reported a trade Oct 1, 2026
Other 8 of 28
- EFFECT Notice that a registration became effective May 13, 2026
- ARS Annual report sent to shareholders Apr 28, 2026
- SEC STAFF LETTER Feb 6, 2025
- EFFECT Notice that a registration became effective Jan 30, 2025
- S-1MEF Jan 30, 2025
- CERT Exchange certified a listing Jan 30, 2025
- CORRESP Reply to SEC staff Jan 30, 2025
- UPLOAD Comment letter from SEC staff Jan 29, 2025
Everything here comes from Maze Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.